Study Assessing Efficacy and Safety of NFL-101 as a Tobacco Cessation Therapy

Summary

CESTO 2 is a 318 participants, 3-arm, multicentric, randomized, double-blind, placebo-controlled Phase II clinical trial. The main objectives are to select the most efficient dose and to assess long-term efficacy of NFL-101 compared to placebo, for abrupt cessation and for reduction before cessation.

Timeline

Start

2021-04-12

Primary completion

2024-04-12

Completion

2024-04-12

Outcome

Met primary endpoint

release “CESTO II trial has thus demonstrated that, even with a limited number of patients, NFL-101 is able to meet the efficacy criteria” nflbiosciences.com ↗

Drugs

Indications